March 3rd Week, 2025 Regulatory Events 🎯 The European commission granted approval to Bristol Myers Squibb’ Breyanzi (lisocabtagene maraleucel; an autologous, anti-CD19 CAR-T) for the treatment of adult patients with ≥3L FL (Ref 1) ❓ How many CAR-Ts are currently approved for FL, and what makes Breyanzi unique? 🎯 The US FDA granted Fast Track Designation (FTD) to Imugene Limited’s azercabtagene zapreleucel (azer-cel; an allogeneic, anti-CD19 CAR-T) for the treatment of R/R

Dear Readers, Welcome to our inaugural CGT Watch newsletter! We’re excited to bring you monthly highlights on novel targets, innovative therapeutic approaches, and emerging companies in the cell and gene therapy space. Since we’re keen to keep things concise and focused, this issue will exclusively cover cell therapies. We’re using a 45-day window for these highlights; from our next issue onward, we’ll transition to a monthly update schedule. Section 1: Key Monthly Updates 🎯